ResearcherUniversity of LübeckActive in the last 2 years
Benjamin Heckelmann
Matched on OpenAlex author ID A5091600254. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2023: 1 paper · 2024: none · 2025: none · 2026: 3 papers
Papers 4
- Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-026-01663-z↗
- Current Advances in Preclinical Patient-Derived Cultivation Models for Individualized Drug Response Prediction in Pancreatic Cancer. Co-author DOI 10.32604/or.2026.075028↗
- L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma Co-author DOI 10.64898/2026.08.10.743835↗
- Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations. Co-author DOI 10.3389/fonc.2023.1230382↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Rüdiger Braun · 4 shared papers, 2023–2026 · strength 1.10
- Paper Current Advances in Preclinical Patient-Derived Cultivation Models for Individualized Drug Response Prediction in Pancr… DOI 10.32604/or.2026.075028↗
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Christoph Röcken · 2 shared papers, 2026 · strength 0.46
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Anna Maxi Wandmacher · 2 shared papers, 2026 · strength 0.46
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Annika Bräuer · 2 shared papers, 2026 · strength 0.46
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Susanne Sebens · 2 shared papers, 2026 · strength 0.46
- Paper L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the… DOI 10.64898/2026.08.10.743835↗
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Tobias Keck · 2 shared papers, 2023–2026 · strength 0.37
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Paper Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell p… DOI 10.3389/fonc.2023.1230382↗
- Louisa Bolm · 2 shared papers, 2023–2026 · strength 0.37
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Paper Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell p… DOI 10.3389/fonc.2023.1230382↗
- Kim C. Honselmann · 2 shared papers, 2023–2026 · strength 0.37
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Paper Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell p… DOI 10.3389/fonc.2023.1230382↗
- Ulrich Friedrich Wellner · 2 shared papers, 2023–2026 · strength 0.37
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Paper Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell p… DOI 10.3389/fonc.2023.1230382↗
- Benedikt Färber · 2 shared papers, 2023–2026 · strength 0.37
- Paper Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarc… DOI 10.1038/s41698-026-01663-z↗
- Paper Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell p… DOI 10.3389/fonc.2023.1230382↗
- Daniela Wesch · 1 shared paper, 2026 · strength 0.23
- Tina Daunke · 1 shared paper, 2026 · strength 0.23
- Anne‐Sophie Mehdorn · 1 shared paper, 2026 · strength 0.23
- Silje Beckinger · 1 shared paper, 2026 · strength 0.23
- Corinna Ulrike Keber · 1 shared paper, 2026 · strength 0.22
- Steffen Deichmann · 1 shared paper, 2026 · strength 0.22
- Jens Uwe Marquardt · 1 shared paper, 2026 · strength 0.22
- Hendrik Ungefroren · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.